Nichole Tucker

In the phase II biomarker-driven trial combining retinoic acid receptor alpha agonist SY-145 with azacitidine, newly diagnosed adult patients with RARA-positive acute myeloid leukemia who were unfit for intensive chemotherapy continued to show responses to the combination and demonstrate tolerability of the regimen, according to a press release from Syros Pharmaceuticals.

In an interview with <em>Targeted Oncology</em>, at the Lynn Sage Breast Cancer Symposium, Susan Domchek, MD, explained the meaning of low to moderate penetrance genes and how they are indicative of breast cancer risk. She also explained the importance of germline and genetic testing to reveal mutations in these genes.&nbsp;

Margetuximab, an investigational monoclonal antibody, prolonged survival in pretreated patients with HER2-positive metastatic breast cancer when combined with chemotherapy, according to the second interim analysis of the phase III SOPHIA trial, which was reported in a press release from MacroGenics.<br /> &nbsp;

The combination of onvansertib, a third-generation adenosine triphosphate inhibitor, with FOLFIRI and bevacizumab achieved positive responses in patients with metastatic colorectal cancer in the second-line setting, according to the results of a phase Ib/II reported in a press release from Trovagene, Inc.<br /> &nbsp;

Bemcentinib, a first-in-class AXL inhibitor, has been approved for a fast track designation by the FDA for the treatment of elderly patients with relapsed or refractory acute myeloid leukemia, according to a press release from BerGenBio.<br /> &nbsp;

The phase I/II CIRLL trial has opened an expansion cohort to include patients with mantle cell lymphoma in the study of the monoclonal antibody, cirmtuzumab, plus ibrutinib. The study was previously open to patients with chronic lymphocytic leukemia and small lymphocytic leukemia only.¹

In the HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine significantly improved progression-free survival in patients with locally advanced, unresectable, or metastatic HER2-positive breast cancer, meeting the primary endpoint of the study, according to a press release from Seattle Genetics.<br /> &nbsp;

In an interview with&nbsp;Targeted Oncology&nbsp;at the ILCA conference, Rimola, radiologist, Radiology Department, Barcelona Clinic Liver Cancer Group, University of Barcelona, explained how assessment criteria may change patterns of progression and ultimately change outcomes in patients with advanced HCC treated with nivolumab.

The triplet combination of abemaciclib, trastuzumab, and fulvestrant showed a significant statistical improvement in progression-free survival compared with chemotherapy and trastuzumab in patients with heavily pretreated, hormone receptor&ndash;positive, HER2-positive breast cancer, according to the results of the phase II monarcHER trial.

The lack of approved therapies to target EGFR exon 20 insertion mutations, the third most common form of EGFR mutations, led to the study of osimertinib in combination with cetuximab in patients with advanced EGFR-mutant non&ndash;small cell lung cancer.<br /> &nbsp;

In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, discussed the results of the BACCI and MOUNTAINEER studies, which showed promise for the use of PD-1/PD-L1 combinations over single-agent treatment in patients with metastatic&nbsp;colorectal cancer.&nbsp;

In an interview with Targeted Oncology, Maha Hussain, MD, discussed targeting DNA repair defects in metastatic castration-resistant prostate cancer with the PARP inhibitor olaparib in the phase III PROfound trial.

In an interview with&nbsp;<em>Targeted Oncology</em> during the 2019 SOHO Annual Meeting, Andrew Kuykendall, MD discussed similarities and differences between fedratinib and ruxolitinib and offered advice to community oncologists who are using JAK inhibition for treating patients with myelofibrosis.

In an interview with&nbsp;<em>Targeted Oncology</em>, Negrao, assistant professor, The University of Texas MD Anderson Cancer Center, reviewed data from the study of response to ICB therapy in patients with oncogene-driven non&ndash;small cell lung cancer.

A pivotal multicenter, open-label, randomized phase III trial has been initiated to evaluate the efficacy and safety of the novel mitochondrial inhibitor, devimistat in combination with a modified FOLFIRNOX regimen for the first-line treatment of patients with metastatic pancreatic cancer, according to a press release from Rafael Pharmaceuticals.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>at the<em>&nbsp;</em>2019<em>&nbsp;</em>Kidney Cancer Research Summit, McGregor, discussed emerging combinations and novel agents for the treatment of RCC.

In an interview with&nbsp;<em>Targeted Oncology</em>, LMichael S. Lee, MD, discussed the early data on the combination of atezolizumab and bevacizumab in patients with unresectable HCC. He also highlighted the importance of further validation, like the phase III IMbrave150 study, which is comparing the combination to the standard of care.

The FDA has granted cobimetinib, a MEK inhibitor, with a breakthrough therapy designation for the treatment of adult patients with histiocytic neoplasms who do not harbor a <em>BRAF</em> V600 mutation.

In an interview with&nbsp;<em>Targeted Oncology</em>, Gregory Gores, MD explained the role of molecular therapy and the use of genetic testing to guide treatment of iCCA.

In an interview with&nbsp;<em>Targeted Oncology</em>, Nicholas J. Vogelzang, MD, FACP, FASCO, explained the need for updates to clinical trial criteria to make checkpoint inhibition more widely available to patients with metastatic bladder cancer.

The FDA has granted a fast track designation to imetelstat for the treatment of adult patients with relapsed or refractory myelofibrosis who have intermediate-2 or high-risk disease. This designation is inclusive of patients with primary MF or those who developed MF after thrombocythemia or polycythemia vera, according to a press release from Geron Corporation, the developer of the drug.<br /> &nbsp;

Best practices for targeting colon cancer was the topic of discussion during a&nbsp;Targeted Oncology live case-based peer perspectives presentation led by John H. Strickler, MD.

In an interview with&nbsp;<em>Targeted Oncology</em>, Marcelo C. Pasquini, MD, discussed the importance of obtaining real-world data and establishing registries for collecting patient outcomes, and how real-world data compare with data from pivotal trials. He also explained the challenges with accessibility to CAR T-cell therapies.

In an interview with <em>Targeted Oncology</em>, Dean A. Fennell, MD, PhD, explained the need for the MIST trial and personalized treatment for patients with mesothelioma.

In an interview with&nbsp;<em>Targeted Oncology</em>, Srdan Verstovsek, MD, PhD, discussed the treatment of MPNs in the community setting and how the field can improve. He also encouraged community oncologist to incorporate quality-of-life measurements and prognostic scoring systems when treating these patients.<br /> &nbsp;

In an interview with <em>Targeted Oncology</em>,<em> </em>Prithviraj Bose, MD, reviewed his thoughts on identifying and treating progression in myelofibrosis, which he recently presented on during the 2019 SOHO Annual Meeting.&nbsp;&nbsp;

In an interview with <em>Targeted Oncology</em>, Jonathan Rosenberg, MD, discussed the ongoing study of durvalumab plus olaparib in patients with metastatic urothelial cancer and other studies that have lain the groundwork for this combination.

In an interview with <em>Targeted Oncology</em>, Simon Rule, MD, gave an overview of the standard of care for MCL, which he recently presented at the 2019 SOHO Annual Meeting.

In an interview with <em>Targeted Oncology</em>, John V. Heymach, MD, PhD, discussed the phase II study to identify mechanisms of acquired poziotinib resistance and the other available agents for targeting <em>EGFR</em> exon 20&ndash;mutant NSCLC.

In an interview with <em>Targeted Oncology</em>, Yi-Long Wu, MD discussed the results of the INSIGHT study and other agents and combinations for the treatment of patients with <em>EGFR</em>-mutant NSCLC.<br /> &nbsp;